|
|
Volumn 45, Issue 4, 2005, Pages 617-625
|
|
Highlights of the 2004 Scientific Sessions of the Heart Failure Society of America, Toronto, Canada, September 12 to 15, 2004
a,b
c
c,d
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
ADENOVIRUS VECTOR;
ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT;
ARGININE;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
BIOLOGICAL MARKER;
BUCINDOLOL;
CLOPIDOGREL;
CRATAEGUS EXTRACT;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
DOXORUBICIN;
ENOXIMONE;
EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;
GEFITINIB;
GLYCINE;
IMATINIB;
LIPOSOME;
LOSARTAN;
NEU DIFFERENTIATION FACTOR;
PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;
PIPERANOMETOZINE;
PROPRANOLOL DERIVATIVE;
PROSTACYCLIN;
PROTEIN KINASE;
PROTEIN KINASE B;
PROTEIN TYROSINE KINASE INHIBITOR;
RECOMBINANT DNA;
TRANSCRIPTION FACTOR;
TRANSCRIPTION FACTOR HIF 1 ALPHA;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
WARFARIN;
ANTICOAGULANT THERAPY;
CANADA;
CARDIOLOGY;
CARDIOTOXICITY;
CELL BASED GENE THERAPY;
CELL PROLIFERATION;
CLINICAL TRIAL;
CONFERENCE PAPER;
DEFIBRILLATOR;
EXERCISE;
GENE MUTATION;
GENETIC POLYMORPHISM;
HEALTH CARE COST;
HEALTH CARE PERSONNEL;
HEART FAILURE;
HEART INFARCTION;
HEART LEFT VENTRICLE EJECTION FRACTION;
HEART MITOCHONDRION;
HEART VENTRICLE REMODELING;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HIGH RISK POPULATION;
HUMAN;
INCIDENCE;
MEDICAL SOCIETY;
MORTALITY;
MYOCARDIAL DISEASE;
NANOTECHNOLOGY;
NONHUMAN;
PRIORITY JOURNAL;
PROGNOSIS;
QUALITY OF LIFE;
REGENERATION;
RISK ASSESSMENT;
SIDE EFFECT;
SIGNAL TRANSDUCTION;
ST SEGMENT ELEVATION;
STROKE;
SURGEON;
SURVIVAL RATE;
TISSUE ENGINEERING;
|
|
EID: 13544263335
PISSN: 07351097
EISSN: None
Source Type: Journal
DOI: 10.1016/j.jacc.2004.11.059 Document Type: Conference Paper |
|
Times cited : (7)
|
|
References (0)
|
